ArticleBreast cancer (Tokyo, Japan)2026
An investigation to identify the factors for negative sentinel lymph node metastasis in early breast cancer cases.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond the triad: biological subtypes and the "safety net" in omitting sentinel lymph node biopsy.Breast cancer (Tokyo, Japan) · 2026Article
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSentinel Lymph Node Biopsy (SLNB) in breast cancer (BC) is a standard procedure. Omission of SLNB in BC is an evolving area in clinical practice and a reasonable option. A retrospective study was conducted to identify cases of negative SLNs.
methodsA total of 1,956 patients who underwent SLNB for cN0 invasive BC and who did not undergo preoperative chemotherapy were included in this retrospective study. Pathological diagnosis using frozen sections or the OSNA method was used for the diagnosis of SLNs. A multivariate analysis of factors for negative SLNs was performed using logistic regression analysis.
resultsMetastasis to SLNs was observed in 379 cases (19.4%). SLN metastasis was not associated with ER, PgR, and HER2 status. A multivariate analysis revealed that the significant factors for negative SLNs were age > 50 years, tumor size ≤ 2 cm and HG of 1. The incidence of SLN metastasis in Luminal B type was significantly higher than the other subtypes, and cases with breast conserving surgery had a significantly lower metastatic rate than total mastectomy. The disease-free survival rate of cases with the above-mentioned factors was favorable regardless of the SLN status.
conclusionMetastasis to SLNs was found in 19.4% of cN0 BC cases. Factors related to negative SLNs were age > 50 years, tumor size ≤ 2cm, and HG of 1, and a positive SLN rate was significantly higher in the Luminal B subtype. The DFS for cases with the above factors was highly favorable. Therefore, conducting SLNB will depend on the above-mentioned characteristics.
Indexed as
Identifiers
41655174What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.